title: Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.
abstract: We performed a retrospective review of side effects and clinical outcomes in relapsing-remitting (RR) multiple sclerosis (MS) patients receiving long-term treatment with daclizumab. Twelve patients with RR MS were initially treated with daclizumab at 1 mg/kg IV, again 14 days later and then monthly treatments (average duration 42.1 months). Daclizumab dose (0.85 mg/kg to 1.5 mg/kg) was adjusted based on clinical response. Daclizumab was generally well tolerated. There was a significant reduction in relapse rate and improvement in Expanded Disability Status Scores (EDSSs) (p < 0.0001). Long-term treatment with daclizumab in RR MS patients has apparent benefit that will require formal confirmation.
authors.affiliation: Neurovirology Research Laboratory, VASLCHCS and Department of Neurology, University of Utah, Salt Lake City, UT, USA.
authors.forename: Monica A
authors.initials: MA
authors.lastname: Rojas
authors.forename: Noel G
authors.initials: NG
authors.lastname: Carlson
authors.forename: Thomas L
authors.initials: TL
authors.lastname: Miller
authors.forename: John W
authors.initials: JW
authors.lastname: Rose